Tvardi Therapeutics, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$3.99
−$0.06 (−1.38%) 4:00 PM ET
Prev closePrevC$4.05
OpenOpen$3.95
Day highHigh$4.18
Day lowLow$3.95
VolumeVol39,722
Avg volAvgVol54,830
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$37.43M
P/E ratio
-0.09
FY Revenue
$9.71M
EPS
-44.92
Gross Margin
63.08%
Sector
Healthcare
AI report sections
MIXED
TVRD
Tvardi Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−14% (Below avg)
Vol/Avg: 0.86×
RSI
56.35(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: -0.00 Signal: -0.01
Short-Term
+0.04 (Strong)
MACD: -0.09 Signal: -0.13
Long-Term
+0.00 (Strong)
MACD: -0.13 Signal: -0.13
Intraday trend score
54.00
LOW50.00HIGH85.50
Latest news
TVRD•5 articles•Positive: 1Neutral: 0Negative: 4
PositiveGlobeNewswire Inc.• Delveinsight
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.
Completed enrollment for Phase II TTI-101 trial with recent positive updates, showing progress in STAT3 inhibitor development for IPF
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics (NASDAQ: TVRD) experienced an 80% stock decline on October 13, 2025, after disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and lung function outcomes. A securities law firm is now investigating potential claims on behalf of affected investors.
The company experienced an 80% stock price decline following the announcement of failed Phase 2 clinical trial results for its lead drug candidate TTI-101. The trial failed to meet its primary efficacy and safety goals, representing a significant setback for the company's pipeline and triggering securities litigation investigations.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics' stock plummeted over 80% on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and efficacy outcomes. Securities law firm Faruqi & Faruqi is investigating potential claims on behalf of affected investors.
The company experienced an 80% stock price decline following disappointing Phase 2 clinical trial results that failed to meet efficacy and safety goals, triggering securities litigation investigation and significant investor losses.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics experienced significant stock decline after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
Stock plummeted over 80% after unsuccessful clinical trial results, with the study failing to meet its primary objectives and demonstrating ineffective treatment outcomes
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics experienced an 80% stock drop after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
Stock plummeted over 80% due to unsuccessful clinical trial results, indicating poor performance and potential investor losses
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
